CAR-T in general is at its infancy when it comes to a marketable product... and if we take the already 5 approved FDA CAR-T therapies as an example, the first approval of a product in a new line of treatment simply leads to a tsunami of research, funding and development in the years to come as every biotech in this spaces aims to improve on the first product approved (which is always going to have room for improvement in terms of response rates, efficacy and safety).
Second gen CAR-T's may be developed into third gen with another costimulatory agent, or combined with inhibitors to improve the treatment over time... .these are only two pathways of many that large pharma and smaller biotechs will invest in after confirmation of a new target i.e. CD-19 is the only approved target by the FDA, and look at the frenzy it has stirred up since.
Anyone want to take a punt at how much our IP is going to be worth when everyone wants a piece of Chlorotoxin? If other companies want to use Chlorotoxin in a CAR-T, CHM could either deny them if it infringes our IP, or agree that CHM get a royalty from future sales from that product using our IP.
CHM Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)